Delivery Order SPE2DB22D3401-SPE2DB25FT5XL
Award Date 8/28/25
Potential Completion Date 8/29/25
Potential Value $42K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,981.84 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pens on October 29, 2025. This non-competitive delivery order, classified as firm fixed price, is set to be completed by October 30, 2025, with performance originating from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat conditions including atopic dermatitis, asthma, and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $94,166.98 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pens on November 24, 2025. This non-competitive, firm fixed price delivery order is scheduled for completion by November 25, 2025, with performance to be fulfilled at the contractor's Conshohocken, Pennsylvania facility. Dupixent (dupilumab) is a monoclonal antibody used to treat moderate-to-severe atopic dermatitis, eosinophilic esophagitis, and other...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,219.89 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 25, 2025. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 28, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to treat moderate-to-severe atopic dermatitis, asthma, and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,279.86 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 16, 2025, with a completion date of July 17, 2025. This firm fixed price delivery order was competitively awarded without a set-aside designation and will be performed at the vendor's corporate office in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat various inflammatory conditions, including...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Dupixent 300 mg/2 mL pens with a ceiling value of $42,441.91. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of September 4, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat various inflammatory and allergic conditions,...
- The Defense Logistics Agency awarded a $31,497.66 delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Dupixent 300 mg/2 mL pens. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by June 3, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat various allergic and inflammatory conditions, including atopic...
- The Defense Logistics Agency awarded a $54,501.62 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injections on August 27, 2025, with ultimate completion by August 28, 2025. This firm fixed-price, competitively awarded contract—without set-aside designation—will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat conditions including atopic dermatitis, asthma, and chronic...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Dupixent 300 mg/2 mL pen injections with a ceiling value of $14,525.26. This firm fixed-price delivery order, which is expected to be completed by August 4, 2025, was competitively awarded with no set-aside designation. The product will be delivered to the prime contractor's location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $50,616.79 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injections on August 20, 2025, with completion expected by August 21, 2025. This firm fixed-price, competitively awarded contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent is a biologic medication commonly used to treat moderate-to-severe atopic dermatitis, asthma, and other...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Dupixent 300 mg/2 ml pens with a ceiling value of $13,120.76. This is a firm fixed-price delivery order with an ultimate completion date of September 2, 2025, and represents a non-competitive, open-market award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic...